Search Weight Loss Topics:

Page 56«..1020..55565758..7080..»

Home » Testosterone » Page 56

Although autoimmune disease (AD) affects both genders, womenare atan overwhelming disadvantage. Of the approximate8% of the population affected by AD, a whopping 78% of those cases are women (NCBI). The National Institutes of Health has officially designated autoimmune disease as a major womens health issue.

Autoimmunity in and of itself is very complicated, withmore than80 diseases under its umbrella. The rate at which AD affects women over men, is no exception to the complexity of understanding this group of diseases. Through recent studies, scientists have found evidence to support three significant theories to explain why women are so greatly affected by AD compared to men.

Testosterone levels protect menAccording to researchers at theUniversity of Gothenburg, there is a link between the male sex hormone testosterone and protection against autoimmune diseases. Men are generally more protected than women, who only have one-tenth as much testosterone. Their study confirmed that this hormone reduces the number of B cells, a type of lymphocyte that releases harmful antibodies.Testosterone suppresses the protein BAFF, which makes the harmful B cells more viable. Therefore, women dont benefit from the same protection against these B cells.

These findings support those of aprevious studyshowing the link between varying levels of BAFF andsystemic lupus erythematosus (SLE), an autoimmune disease that affects nine women for every one man. Lupus is one of the most common autoimmune diseases among women.

SkinPerhaps one of the most interesting findings was uncovered in a study at The University of Michigan three years ago. Researchers discovered that women carry more of a molecular switch, called VGLL3, in their skin than men do. In2019, further research pointed to evidence showing that having too much VGLL3 in skin cells pushes the immune system into overdrive, leading to a self-attacking autoimmune response that can extend beyond the skin, also attacking internal organs.

The same gene expression-level changes in skin cells with extra VGLL3 are also seen in autoimmune diseases such as lupus. It is still not known why women have more VGLL3 in their skin than men. However, men with lupus do show the same VGLL3 pathway activated as in women with lupus.

The Pregnancy Compensation Hypothesis and hormonesThe idea behind this theory is that a womans immune system evolves to support the heightened need for protection during pregnancy. According to Melissa Wilson, PhD and senior author of astudyconducted at Arizona State University, reduced pregnancy rates in todays modern, industrialized societies means womens immune systems dont have the reproductive challenges they are meant to stand up against. These changes in the reproductive ecology of women makes them more susceptible to autoimmune disease because immune surveillance is heightened.

Continued here:
New Theories Explaining Why Women are More Susceptible to Autoimmune Disease than Men - Managed Healthcare Executive

A first-of-its-kind study published by Fertility and Sterility revealed that transgender men have a similar response to ovarian stimulation as cisgender women, even after theyve been using testosterone for years.

The aim of the study was to investigate the outcomes of assisted reproductive technology in trans men and compare those to a matched group of cisgender women to see if testosterone had a noticeable impact on fertility through egg freezing, in vitro fertilization, and other forms of assisted fertility.

Researchers reviewed the records of 26 trans males and 130 cisgender women who sought care from 2010 to 2018. The majority of trans males (61 percent) had received testosterone hormonal therapy but were off the hormone a mean of four months before starting assisted reproductive therapy. The mean time they were on testosterone before seeking fertility assistance was 3.7 years (however, the range spanned from three months to 17 years).

In all 26 cases, the trans men had viable eggs retrieved, with an average of 20 eggs per person. Overall, 16 out of the 26 trans men only had eggs retrieved and preserved in a cryogenic bank, while seven had fresh or frozen egg transfers.

Of those seven, two carried the babies themselves while the remaining five had transferred embryos implanted in cisgender female partners. All of the pregnancies were successfully carried to term, ending in live births.

The study itself is groundbreaking for trans men who dream of having biological children but are worried about how testosterone use interacts with fertility. It should also encourage doctors who have shown reluctance in referring their trans patients to a fertility practice to reconsider.

Before this study, we did not know if long-term testosterone use had a negative impact on egg reserve but, remarkably, testosterone does not appear to have an effect on the ovarian reserve as measured by egg count, researcher Nina Resetkova told Medscape Medical News. Trans males worry that theyve thrown in the towel, and by committing to testosterone have started on a pathway with no return, but these data suggest they still have options.

Resetkova did caution that trans men who undergo puberty blockers as teens may see those options curtailed. We have little data so its hard to be conclusive, but its unlikely these patients would have mature hormonal responses and the ovaries might be in a naive state, she hypothesized.

Acknowledging that the study was limited by size, Resetkova noted that it found ovarian stimulation outcomes that are similar to those of cisgender counterparts, and this seems to be true even in cases of patients who have already initiated hormonal transition with the use of testosterone.

Read more here:
Is There New Hope for Trans Men Trying to Give Birth? - Advocate.com

Our latest research report entitle global Testosterone Replacement Therapy market provides comprehensive and deep insights into the market dynamics and growth of Global Testosterone Replacement Therapy Industry. Latest information on market risks, industry chain structure, Testosterone Replacement Therapy cost structure and opportunities are offered in this report. The entire industry is fragmented based on geographical regions, a wide range of applications and Global Testosterone Replacement Therapy Market types. The past, present and forecast market information will lead to investment feasibility by studying the crucial Global Testosterone Replacement Therapy Industry growth factors.

Global Testosterone Replacement Therapy Market Analysis By Major Players:

AbbviePfizerEli LillyTeva PharmaceuticalsMylanBayer Healthcare PharmaceuticalsAntares PharmaFerring PharmaceuticalsAllerganAntares PharmaSandozClarus TherapeuticsJuniper PharmaceuticalsEndo InternationalAcerus PharmaceuticalsForendo PharmaMetp PharmaRepros Therapeutics

Get FREE Sample Report Copy @ https://www.globalmarketers.biz/report/business-services/2018-global-testosterone-replacement-therapy-industry-research-report/118104#request_sample

By Product Type:

GelsInjectablesPatchesOther

By End-User

HospitalsClinicsOther

Global Testosterone Replacement Therapy Market Analysis By Geographical Zones:

Europe Testosterone Replacement Therapy Market (Germany, France, Italy, Russia and UK)

North America Testosterone Replacement Therapy Market (Canada, USA and Mexico)

Latin America Testosterone Replacement Therapy Market (Middle and Africa).

Testosterone Replacement Therapy Market in Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Asia-Pacific Testosterone Replacement Therapy Market (South-east Asia, China, India, Korea and Japan).

Global Testosterone Replacement Therapy Market news, plans & policies, market drivers, analysis of upstream raw material suppliers and downstream buyers of Testosterone Replacement Therapy is carried out in this report. On regional and country level market share, production value, gross margin analysis, consumption ratio, import-export scenario, and SWOT analysis is covered. Global Testosterone Replacement Therapy Industry forecast study enlists the market value (in USD) and volume forecast for each region, product type, and applications.

Inquiry Here For Detail Report @ https://www.globalmarketers.biz/report/business-services/2018-global-testosterone-replacement-therapy-industry-research-report/118104#inquiry_before_buying

To Provide A Clear Global Testosterone Replacement Therapy Market Structure The Report Is Divided Into 12 Chapters As Follows:

Chapter 1, states the product definition, specifications, pictures, classification and varied applications of Global Testosterone Replacement Therapy Industry;

Chapter 2, covers the price structure and Market structure covering the cost of raw materials, manufacturing cost, supplier detail of Testosterone Replacement Therapy Market;

Chapter 3, lists the technical specifications of Testosterone Replacement Therapy covering the capacity, production volume, manufacturing base, R&D status, and sources;

Chapter 4, represents the market analysis, sales channel, pricing trend, and import-export scenario of Testosterone Replacement Therapy;

Chapter 5 and 6, studies the regional presence of Global Testosterone Replacement Therapy market across North America, Europe, Asia-Pacific, Latin America, Middle East & Africa. Also, Testosterone Replacement Therapy Market analysis by Type is covered in this report;

Chapter 7 and 8, Testosterone Replacement Therapy market analysis by application and major manufacturers is covered in this report;

Chapter 9, Global and Regional Testosterone Replacement Therapy Industry trend analysis by different applications and product types is mentioned in this chapter;

Chapter 10, Enlist the regional and international Testosterone Replacement Therapy import-export scenario, utilization ratio, and supply chain analysis;

Chapter 11, The consumer analysis is covered in this chapter;

Chapter 12, presents the key research findings, conclusion, analyst views, data sources, and in-depth research methodology;

Enquire Here For Discount :https://www.globalmarketers.biz/discount_inquiry/discount/118104

Major points from Table of Contents for Global Testosterone Replacement Therapy Industry 2020 Market Research Report include:

1 Testosterone Replacement Therapy Market Overview

2 Global Testosterone Replacement Therapy Market Competition by Manufacturers

3 Global Testosterone Replacement Therapy Capacity, Production, Revenue (Value) by Region (2020-2026)

4 Global Testosterone Replacement Therapy Industry Supply (Production), Consumption, Export, Import by Region (2020-2026)

5 Global Testosterone Replacement Therapy Production, Revenue (Value), Price Trend by Type

6 Global Testosterone Replacement Therapy Market Analysis by Application

7 Global Testosterone Replacement Therapy Industry Manufacturers Profiles/Analysis

8 Testosterone Replacement Therapy Manufacturing Cost Analysis

9 Industrial Chain, Sourcing Strategy and Downstream Buyers

10 Marketing Strategy Analysis, Distributors/Traders

11 Market Effect Factors Analysis

12 Global Testosterone Replacement Therapy Market Forecast (2020-2026)

13 Research Findings and Conclusion

14 Appendix

Explore Full Report With Detailed TOC Here @ https://www.globalmarketers.biz/report/business-services/2018-global-testosterone-replacement-therapy-industry-research-report/118104#table_of_contents

Here is the original post:
Testosterone Replacement Therapy Market Sales Segmentation and Analysis by Recent Trends, Development and Growth Factors by Regions Overview to 2026 -...

LAUSANNE, Switzerland and WAYNE, Pa., June 9, 2020 /PRNewswire/ -- Debiopharm, a Swiss-based, biopharmaceutical company, and Verity Pharmaceuticals Inc., a US based specialty pharmaceutical company focused on therapeutic solutions for genitourinary (GU) diseases, today announced having entered into an exclusive agreementthat grants Verity Pharmaceuticals Inc., in the United States of America, the rights to commercialize Trelstar (triptorelinpamoate for injectable suspension)a hormone therapy for patients living with prostate cancer. The North American based company will take on US commercialization activities in this 20-year, extendable agreement for the brand used in the palliative treatment of prostate cancer.

Verity Pharma is dedicating resources to ensuring that physicians and patients are aware of the proven, consistent efficacy of Trelstar and how it may fit into their prostate cancer treatment plans. The availability of Triptorelin for patients around the world is the result of Debiopharm's expertise in oncology drug development & manufacturing. First registered in France in 1986, triptorelin is currently marketed in more than 80 countries and is a market leader in many territories worldwide.

"Trelstar has been proven to help patients keep castrate-resistant prostate cancer (CRPC) at bay, which has significant implications on their quality of life," said Dr. Neil Fleshner, CMO of Verity Pharma. "As we all grapple with the effects of the COVID-19 pandemic, it is also beneficial that this medicine can be administered as infrequently as once every six months while still effectively and consistently keeping testosterone levels down."

Additionally, Verity Pharma's pipeline has two promising bladder cancer drugs, one in Phase II, and another in preregistration and looks forward to continuing to provide innovative and effective pharmaceutical solutions to Americans living with genitourinary diseases. Debiopharm's cancer therapy pipeline also continues to expand, including phase I, II and phase III ready compounds for a variety of tumor types such as Head & Neck cancer and Non-Hodgkin's Lymphoma.

"Verity Pharma'sstrong focus in uro-oncology and seasoned management team make it an ideal alliance partner for the Trelstar brand," explained Bertrand Ducrey, CEO of Debiopharm. "Their scientific, sales and market access teams clearly add value and the expertise necessary to relaunch Trestar in the US."

"At Verity Pharma we do not simply distribute medicines, but partner with physicians and their patients to support them on their treatment journeys," said Howard Glase, CEO of Verity Pharma. "Thousands of people across the country already know just how impactful Trelstar is and we look forward to breathing new life into this important therapy."

Prostate cancer is the second-leading cause of cancer-related deaths amongst American men, with nearly 200,000 new cases diagnosed each year. Trelstar, an androgen deprivation therapy (ADT), is indicated for the palliative treatment of advanced prostate cancer. It is a gonadotropin-releasing hormone (GnRH) agonist that works by decreasing the amount of testosterone in the body and maintaining it below castration levels. For patients with prostate cancer, this course of treatment can help control or stop the growth of prostate cancer cells. It can also help delay the progression to CRPC.

About Prostate Cancer Treatment In the fight against prostate cancer, it is critical to bring testosterone levels down and keep them down and Trelstar has been shown to deliver lower, more consistent serum testosterone levels.

Maintaining consistently low levels of testosterone can extend the time CRPC by 10 years (median). This means patients are able to hold off on expensive, final stage treatments that have been associated with significant side effects and deterioration in quality of life. Trelstar helps patients to bring down testosterone levels and effectively keep them down over time.

About Trelstar (triptorelin)

Trelstar (triptorelin) is an agonist analogue of the natural gonadotropin-releasing hormone (GnRH). It is the only GnRH agonist that differs from natural GnRH by a single amino acid. Trelstar has been engineered to deliver superagonist activity and works by decreasing the amount of certain hormones in the body. This is referred to as androgen deprivation therapy or ADT. Debiopharm has developed three sustained-release formulations (1, 3 and 6 months) of triptorelin pamoate. In the US, triptorelin is registered for Prostate Cancer as Trelstar and was first approved and launched in 2000 for the palliative treatment of hormone dependent advanced carcinoma of the prostate gland. Trelstar has been in use as a trusted ADT in the United States for almost 20 years.

To learn more about Trelstar please see the Trelstar Prescribing Information or visit http://www.trelstar.com

About Debiopharm Debiopharm develops innovative therapies that target high unmet medical needs in oncology and bacterial infections. Bridging the gap between discovery products and real-world patient reach, they in-license high-potential compounds, clinically demonstrate their safety and efficacy and then select pharmaceutical commercialization partners to maximize patient access.

Visit us http://www.debiopharm.com/Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews

About Verity Pharma Verity Pharma is a specialty pharmaceutical company focused on therapeutic solutions for genitourinary (GU) diseases.

Every day the Verity Pharma team goes to work with an unflinching conviction to deliver meaningful solutions to healthcare professionals and their patients.

Verity Pharma works with best in class global pharmaceutical manufacturing partners to ensure that product quality and availability is a constant deliverable.

We are also committed to supporting programs, initiatives and organizations that help improve health, expand research opportunities, and promote education in the growing area of genitourinary diseases and disorders.

For more information visit http://www.veritypharma.com

Continue reading here:
Debiopharm partners with Verity Pharmaceuticals for the exclusive US commercialization of Trelstar for Prostate Cancer - The Delaware County Daily...

A new market report by Market Research Intellect on the Testosterone Booster Market has been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis of the global market, including qualitative and quantitative insights, historical data, and estimated projections about the market size and share in the forecast period. The forecasts mentioned in the report have been acquired by using proven research assumptions and methodologies. Hence, this research study serves as an important depository of the information for every market landscape. The report is segmented on the basis of types, end-users, applications, and regional markets.

The research study includes the latest updates about the COVID-19 impact on the Testosterone Booster sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.marketresearchintellect.com/download-sample/?rid=230530&utm_source=COD&utm_medium=888

The report also emphasizes the initiatives undertaken by the companies operating in the market including product innovation, product launches, and technological development to help their organization offer more effective products in the market. It also studies notable business events, including corporate deals, mergers and acquisitions, joint ventures, partnerships, product launches, and brand promotions.

Leading Testosterone Booster manufacturers/companies operating at both regional and global levels:

Sales and sales broken down by Product:

Sales and sales divided by Applications:

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

The report also focuses on the global industry trends, development patterns of industries, governing factors, growth rate, and competitive analysis of the market, growth opportunities, challenges, investment strategies, and forecasts till 2026. The Testosterone Booster Market was estimated at USD XX Million/Billion in 2016 and is estimated to reach USD XX Million/Billion by 2026, expanding at a rate of XX% over the forecast period. To calculate the market size, the report provides a thorough analysis of the market by accumulating, studying, and synthesizing primary and secondary data from multiple sources.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=230530&utm_source=COD&utm_medium=888

The market is predicted to witness significant growth over the forecast period, owing to the growing consumer awareness about the benefits of Testosterone Booster. The increase in disposable income across the key geographies has also impacted the market positively. Moreover, factors like urbanization, high population growth, and a growing middle-class population with higher disposable income are also forecasted to drive market growth.

According to the research report, one of the key challenges that might hinder the market growth is the presence of counter fit products. The market is witnessing the entry of a surging number of alternative products that use inferior ingredients.

Key factors influencing market growth:

Reasons for purchasing this Report from Market Research Intellect

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=230530&utm_source=COD&utm_medium=888

Customization of the Report:

Market Research Intellect also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

To summarize, the Testosterone Booster market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Go here to read the rest:
Testosterone Booster Market 2019 Break Down by Top Companies, Countries, Applications, Challenges, Opportunities and Forecast 2026 - Cole of Duty

When it comes to surviving critical cases of COVID-19, it appears that men draw the short straw.

Initial reports from China revealed the early evidence of increased male mortality associated with COVID. According to the Global Health 50/50 research initiative, nearly every country is now reporting significantly higher COVID-19-related mortality rates in males than in females as of June 4. Yet, current data suggest similar infection rates for men and women. In other words, while men and women are being infected with COVID-19 at similar rates, a significantly higher proportion of men succumb to the disease than women, across groups of similar age. Why is it then that more men are dying from COVID-19? Or rather, should we be asking why are more women surviving?

I am an immunologist, and I explore how stress and biological sex can impact a persons vulnerability to immune-mediated disease. I study a specific immune cell called the mast cell. Mast cells play a pivotal role in our immune systems as they act as first responders to pathogens and orchestrate immune responses that help clear the invading pathogens.

Our research shows that mast cells from females are able to initiate a more active immune response, which may help females fight off infectious diseases better than men. But the trade-off may be that women are at higher risk for allergic and inflammatory diseases. Recent evidence indicates that mast cells are activated by SARS-CoV-2 which causes COVID-19.

Some clues to why females have higher survival rates may be found in our current understanding of differences in the immune systems of men versus women.

Could sex differences in immune system play a role?

In general, females have a more robust immune response than men which may help females fight off infections better than males. This could be a result of genetic factors or sex hormones such as estrogen and testosterone.

Biological females have two copies of the X chromosome, which contains more immune genes. While the genes on one X chromosome are mostly inactive, some immune genes can escape this inactivation, leading to double the number of immune-related genes and thus double the quantity of certain immune proteins compared with biological men who have only one X chromosome.

Sex hormones such as estrogen and testosterone can also impact the immune response. In one study, researchers showed that activating the estrogen receptor in female mice provided them protection against SARS-CoV. And there is an approved clinical trial that will examine the effects of estrogen patches on the severity of COVID-19 symptoms.

It is, however, interesting that the current data showing that women have better survival rates than men applies to even men and women in the 80-plus age group, when hormone levels in both sexes equalize. This suggests that factors other than adult sex hormone levels are contributing to sex differences in COVID-19 mortality.

Androgens, a group of hormones - including testosterone - that are best known to stimulate the development of male characteristics and can cause hair loss, have also received recent attention as a risk factor for COVID-19 in males. In a study conducted in Italy, prostate cancer diagnosis increased the risk for COVID-19. However, prostate cancer patients who were receiving androgen-deprivation therapy (ADT), a treatment that suppresses the production of androgens which fuels prostate cancer cell growth, had a significantly lower risk for SARS-CoV-2 infection. This suggests that blocking androgens in men was protective against SARS-CoV-2 infection.

It is unknown how ADT works to reduce infection rates in men and whether this has been shown in other countries has yet to be determined. Testosterone, which is an androgen hormone has immune-suppressive effects so one explanation could be that ADT might boost the immune system to combat SARS-CoV-2 infection.

There is also evidence that males and females have different quantities of certain receptors that recognize pathogens or that serve as an invasion point for viruses like SARS-CoV-2. One example is the quantity of angiotensin converting enzyme 2 (ACE2) receptors, which SARS-CoV-2 binds to in order to infect cells. While there is currently no conclusive evidence for a role of ACE2 receptors impacting sex differences and the severity of COVID-19 disease, it remains a potential contributing factor.

Gender, sex and COVID-19 risk

A number of factors can interact with biological sex to increase or decrease ones susceptibility to COVID-19. Another major factor is gender, which refers to social behaviors or cultural norms that society deems appropriate. Males may be at increased risk for severe disease, because in general, they tend to smoke and drink more, wash their hands less frequently and often delay seeking medical attention. All of these gender specific behaviors may put men at higher risk. While there is no current data yet on how gender plays a role in COVID-19, it will be a critically important factor to account for in order to understand sex differences in mortality.

Age, psychological stress level, coexisting conditions such as obesity, diabetes and cardiovascular disease can also interact with biological sex to increase disease.

While COVID-19 highlights the importance of biological sex in disease risk, sex biases in disease in general is not a new concept. COVID-19 is just another example of a disease that will be added to the growing list of diseases for which males or females are at increased risk.

A history of male-biased research

You might be wondering that if biological sex is so important, then why dont we know what is causing disparities in disease prevalence between the sexes and why are there no sex-specific therapies?

One major reason is when it comes to being included in scientific research, it is mostly males who have been studied.

This disparity between biological sex differences in research has only recently been remedied. It has only been in the last five years that the National Institutes of Health has required sex difference data to be collected for all newly funded preclinical research grants.

While there may be several reasons for choosing one sex over the other in research, the huge disparity that now exists is likely a major reason why we still know relatively little about sex differences in immunity, including the current COVID-19 pandemic.

This has clearly hindered advancement of womens health, but also has negative consequences for mens health. For example, given the biological differences between the sexes, it is very possible that drugs and therapies will have different effects in females than males.

Biological sex is clearly a major factor determining disease outcomes in COVID-19. Precisely how your biological sex makes you more or less resilient to diseases such as COVID-19 remains to be elucidated. Future basic research with animals and clinical trials in people need to consider biological sex as well as interactions with gender as an important variable.

[Get facts about coronavirus and the latest research. Sign up for The Conversations newsletter.]

Adam Moeser, Matilda R. Wilson Endowed Chair, Associate Professor of Large Animal Clinical Sciences, Michigan State University

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Image: Reuters

Continue reading here:
Why Do Men Suffer from Coronavirus at a Higher Rate than Women? - The National Interest

A new market report by Market Research Intellect on the Testosterone Cypionate Competitive Market has been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis of the global market, including qualitative and quantitative insights, historical data, and estimated projections about the market size and share in the forecast period. The forecasts mentioned in the report have been acquired by using proven research assumptions and methodologies. Hence, this research study serves as an important depository of the information for every market landscape. The report is segmented on the basis of types, end-users, applications, and regional markets.

The research study includes the latest updates about the COVID-19 impact on the Testosterone Cypionate Competitive sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.marketresearchintellect.com/download-sample/?rid=230846&utm_source=COD&utm_medium=888

The report also emphasizes the initiatives undertaken by the companies operating in the market including product innovation, product launches, and technological development to help their organization offer more effective products in the market. It also studies notable business events, including corporate deals, mergers and acquisitions, joint ventures, partnerships, product launches, and brand promotions.

Leading Testosterone Cypionate Competitive manufacturers/companies operating at both regional and global levels:

Sales and sales broken down by Product:

Sales and sales divided by Applications:

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

The report also focuses on the global industry trends, development patterns of industries, governing factors, growth rate, and competitive analysis of the market, growth opportunities, challenges, investment strategies, and forecasts till 2026. The Testosterone Cypionate Competitive Market was estimated at USD XX Million/Billion in 2016 and is estimated to reach USD XX Million/Billion by 2026, expanding at a rate of XX% over the forecast period. To calculate the market size, the report provides a thorough analysis of the market by accumulating, studying, and synthesizing primary and secondary data from multiple sources.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=230846&utm_source=COD&utm_medium=888

The market is predicted to witness significant growth over the forecast period, owing to the growing consumer awareness about the benefits of Testosterone Cypionate Competitive. The increase in disposable income across the key geographies has also impacted the market positively. Moreover, factors like urbanization, high population growth, and a growing middle-class population with higher disposable income are also forecasted to drive market growth.

According to the research report, one of the key challenges that might hinder the market growth is the presence of counter fit products. The market is witnessing the entry of a surging number of alternative products that use inferior ingredients.

Key factors influencing market growth:

Reasons for purchasing this Report from Market Research Intellect

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=230846&utm_source=COD&utm_medium=888

Customization of the Report:

Market Research Intellect also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

To summarize, the Testosterone Cypionate Competitive market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Go here to see the original:
Testosterone Cypionate Competitive Market 2019 Break Down by Top Companies, Countries, Applications, Challenges, Opportunities and Forecast 2026 -...

Scientists from Russia have established a link between CoVID-19 and testosterone. While studying three groups of men infected with the coronavirus, they have identified different concentrations of the mentioned hormone.

In experiments took part 16 patients with a diagnosis of CoVID-19 aged 28-81 years. Professor Svetlana Kalinchenko, head of the Department of holistic medicine and endokrinologii, told about the development. Experts have studied saliva samples with the aim to identify the characteristics of a steroid profile, with patients divided into three groups. The first group included persons infected with the coronavirus that has the mild form of the disease, and the levels of testosterone they made up of 72.5 PG/ml. the second group included men with moderate and severe forms of the disease, and the amount of hormone they recorded at the level of 61.9 PG/ml.

In the third group were patients with severe leakage oVID-19. The concentration of testosterone in the blood of patients was 61.9 PG/ml. Scientists concluded that a deficiency of this hormone has an impact on the immune status of the organism. A steroid profile of saliva in individuals infected with the coronavirus, should be defined in the complex diagnosis of this disease.

Visit link:
Scientists from Russia have established a link between coronavirus and testosterone - The Times Hub

New York City, United States The effect of the coronavirus pandemic and the lockdown it activated is unmistakably obvious in budgetary markets. Yet, there is still no clearness on the more profound effect that it is having across organizations and modern areas. In view of evaluations made by various examiners and industry body Ficci, here is an effect investigation in human services area.

According to Persistence Market Researchs new report, globalmale hypogonadism marketis slated to exhibit a steady expansion throughout the forecast period (2017-2026). Revenues from the global market for male hypogonadism are estimated to exceed US$ 3,300 Mn by 2026-end.

Governments Taking Initiatives to Spread Awareness about Male Hypogonadism Therapeutics

Lack of sex hormones, usually referred to as male hypogonadism has resulted into many health risks that include osteoporosis, heart disease, and cardiovascular diseases on the back of thinning of bones. Global male hypogonadism market comprises several patented brands that currently have high market penetration. Proliferation in geriatric population in tandem with rising incidences related to rheumatoid arthritis and obesity have been primary factors affecting prevalence of male hypogonadism globally.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/22303

Company Profiles

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/22303

Mounting incidences of testosterone deficiency in male population is a key factor that prevalence of male hypogonadism has surged worldwide. Several governments around the world have been taking initiatives to spread the awareness on hypogonadism treatment procedures, for example testosterone replacement therapy (TST), in order to relieve the painful burden on patients and their families.

As low testosterone levels are increasingly associated with exacerbation of chronic conditions, it further results into disorders apropos to hypothalamic-pituitary-gonadal axis. Advent of TST has however enabled reduction in cases of male hypogonadism considerably. With growing awareness related to its treatment among patients, the market is likely to gain an uptick during the forecast period.

Rising availability of the selective androgen receptor modulators (SARMs) has further sustained the market expansion. The development and high availability of SARMs has led toward the provision of improved treatment procedure to patients having androgen deficiencies, thereby influencing the market growth.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/22303

North America will continue to Dominate Global Male Hypogonadism Market

North America will continue to dominate the global male hypogonadism market, with more than one-third revenue share during the forecast period. In addition, revenues from the male hypogonadism market in North America will exhibit the fastest expansion through 2026, as compared to those from all the other regional segments comprised in the report. Europe and Asia-Pacific excluding Japan (APEJ) are also expected to remain lucrative for the male hypogonadism market. The market in APEJ will ride on a slightly higher CAGR than that in Europe through 2026.

Topical gels are expected to remain the most lucrative among drugs available for treatment of male hypogonadism globally, with sales projected to register the fastest expansion through 2026. Injectables will also remain a major revenue contributor to the market. Sales of injectable and transdermal patches are poised to reflect an equal CAGR through 2026.

Testosterone Replacement Therapy to Remain Preferred among Patients

Based on therapy, testosterone replacement therapy is expected to remain preferred among patients with male hypogonadism worldwide. Roughly 66% revenue share of the market is expected to be held by revenues from testosterone replacement therapy by 2026-end. Revenues from gonadotropin replacement therapy will remain slightly more than half revenues gained from testosterone replacement therapy throughout the forecast period.

Klinefelters syndrome is expected to remain the most prevalent disease type observed in the male hypogonadism market, and revenues from treatment of this disease will exceed US$ 1,800 Mn by 2026-end. Kallmann Syndrome and Pituitary Adenomas among disease types will also account for major revenue shares of the market by 2026-end.

Read the original:
Male Hypogonadism Market Future Growth by In Depth Industry Analysis, Size, Trends and Forecast to 2026 - Cole of Duty

Sammy Sosas Long Gone Summer was a seemingly endless joyride.

But Sosas later years in Chicago featured a corked bat, a smashed boombox, a premature walk-out and a memorable incident with Rick Reilly, then the back-page Life of Reilly columnist for Sports Illustrated.

Reilly had read Sosas remark that hed be first in line for steroid testing once the players union approved it.

He said: I want to be the first to be tested. I want to show everybody Im clean, Reilly remembered. I was dumb enough to think he might go, like he was really serious.

Before a June 2002 game at Wrigley Field, Reilly approached Sosa for an interview. After asking some tame questions, Reilly pulled out a 3-by-5-inch index card and told him: I found a place nearby where you can go and get tested. Youll get the results in a week.

Foam was coming out of his mouth, Reilly recalled in a phone interview. His eyes got the size of small dinner plates and he started screaming at me in Spanish and English. In Spanish it was something about my mother. In English it was: You think youre my father?

He said: Youre gonna get me in trouble! Well, what trouble could there be if youre clean? That really (ticked) him off. He said: Youre trying to get me thrown out of the players union.

Sosa had a point. Going rogue would not have earned him plaudits in the clubhouse.

He screamed at me: I look like this because I work out three times a day in the offseason, Reilly said. I wanted to say: Yeah, thats the beauty of steroids. Steroids themselves dont make you big; they give you the energy and the drive and the testosterone to work out three times a day. ...

Reilly, an 11-time National Sportswriter of the Year, wrote in his SI column then: The funny thing is, I doubt Sosa is on steroids. He has never missed more than six games in any of the last five seasons But plenty of people wonder: Heres a guy who went nine years without ever hitting more than 40 home runs. In the last four seasons hes hit 66, 63, 50 and 64. Heres a guy who was once a skinny, 165-pound, jet-footed Texas Ranger. Now hes a bulky, 230-pound Mr. Olympus.

Looking back, Reilly said, hes surprised he wrote that.

Now we know he was about as clean as a mafia accountant, he said.

Distributed by Tribune Content Agency, LLC.

Continued here:
Sportswriter Rick Reilly recalls the time he called Sammy Sosa on his bluff - South Bend Tribune

Page 56«..1020..55565758..7080..»

Home » Testosterone » Page 56